A Phase 2 interventional study of Tezepelumab and Placebo in Atopic Dermatitis, sponsored by Amgen. Terminated at 86 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-03-10.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Dermatitis, Atopic by Amgen — none open to participants now, none under way, none of them phase 3. Dermatitis, Atopic · Amgen.
Among the 15 studies in Dermatitis, Atopic by Amgen, this one is the 6th largest by enrollment, is the only one that started in 2019, is one of 2 in phase 2, and was the 3rd registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →None of the 15 studies in Dermatitis, Atopic by Amgen is open now. The open studies under Dermatitis, Atopic, anywhere →
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 251 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 231 across the 15 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Dermatitis, Atopic by Amgen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase 2b study is designed to evaluate the safety and efficacy of tezepelumab as a monotherapy and explore its efficacy as adjunct therapy in subjects with moderate-to-severe atopic dermatitis (AD).
All subjects will receive a subcutaneous (SC) dose of either investigational product or placebo as the first dose on day 1.
Subjects who are determined to be non-responders in Part A will receive tezepelumab SC every 2 weeks (Q2W) following completion of all week 16 study activities. Nonresponders are defined as those subjects who have not achieved at least a 50% improvement in Eczema Area and Severity Index (EASI) at week 16 compared to baseline (day 1).
Safety follow-up is 18 weeks after the end of treatment (EOT) visit (20 weeks after the final dose of investigational product).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented recent history (within 12 months before the screening visit) of inadequate response totreatment with topical TCS or subjects for whom topical treatments are otherwise medically inadvisable (ie, because of important side effects or safety risks).
Exclusion Criteria:
Subjects who, in the opinion of the investigator, have evidence of active tuberculosis (TB), either treated or untreated, or a positive QuantiFERON-tuberculosis Gold (QFT-G) test for TB during screening. Subjects with an indeterminate QFT-G may be enrolled if they have ALL of the following:
Prior/Concomitant Therapy:
Other Exclusions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matching placebo administered via SC injection Q2W for a maximum of 52 weeks. Participants defined as non-responders (those who do not achieve at least 50% improvement in EASI at Week 16 compared to baseline) will switch to receive tezepelumab 420 mg SC injection Q2W for the remainder of the study beginning with the Week 18 dose.
Other: Placebo
Tezepelumab 210 mg administered via SC injection once every 4 weeks (Q4W) from Week 4 for a maximum of 52 weeks. All participants randomized to tezepelumab will receive 420 mg SC injection as their first dose. Participants will then receive a placebo at Week 2 to maintain blinding. Participants defined as non-responders (those who do not achieve at least 50% improvement in EASI at Week 16 compared to baseline) will switch to receive tezepelumab 420 mg SC injection Q2W for the remainder of the study beginning with the Week 18 dose.
Drug: Tezepelumab
Tezepelumab 280 mg administered via SC injection Q2W from Week 2 for a maximum of 52 weeks. All participants randomized to tezepelumab will receive 420 mg SC injection as their first dose. Participants will then receive their randomized dose of 280 mg Q2W from Week 2. Participants defined as non-responders (those who did not achieve at least 50% improvement in EASI at Week 16 compared to baseline) will switch to receive tezepelumab 420 mg SC injection Q2W for the remainder of the study beginning with the Week 18 dose.
Drug: Tezepelumab
Tezepelumab 420 mg administered via SC injection Q2W for a maximum of 52 weeks.
Drug: Tezepelumab
Matching placebo administered via SC injection Q2W with topical corticosteroids (TCS) for a maximum of 52 weeks.
Drug: Tezepelumab
Tezepelumab 420 mg administered via SC injection Q2W with TCS for a maximum of 52 weeks.
Drug: Tezepelumab
Solution for injection
Also known as: AMG157
Placebo solution for injection
Number of Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) (IGA 0/1) at Week 16
The IGA allows investigators to assess overall disease severity at 1 given time point and consists of a 6-point severity scale from clear to severe disease * 0 = clear * 1 = almost clear * 2 = mild disease * 3 = moderate disease * 4 = severe disease * 5 = very severe disease The IGA uses clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines for the overall severity assessment (Breuer et al, 2004). Participants who took rescue medication between Day 29 to Week 16 were considered non-responders.
Time frame: Week 16
Number of Participants Who Experienced a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) at Week 16
The EASI evaluates 4 natural anatomical regions for severity and extent of key disease signs and focuses on key acute and chronic signs of inflammation (ie, erythema, induration/papulation, excoriation, and lichenification). A reduction in the EASI score indicates an improvement in severity. Participants who took rescue medication between Day 29 to Week 16 were considered non-responders.
Time frame: Baseline and Week 16
Number of Participants Who Experienced a 50% or 90% Reduction From Baseline in Eczema Area and Severity Index (EASI 50/90) at Week 16
The EASI evaluates 4 natural anatomical regions for severity and extent of key disease signs and focuses on key acute and chronic signs of inflammation (ie, erythema, induration/papulation, excoriation, and lichenification). A reduction in the EASI score indicates an improvement in severity. Participants who took rescue medication between Day 29 to Week 16 were considered non-responders.
Time frame: Baseline and Week 16
Time to Achievement of 50%, 75% or 90% Reduction From Day 1 in Eczema Area and Severity Index (EASI 50/75/90)
Time frame: Day 1 up to End of Study Visit (Week 70)
Change From Baseline in Scoring of Atopic Dermatitis (SCORAD) at Week 16
The SCORAD is a clinical tool for assessing the severity (ie, extent, intensity) of atopic dermatitis (AD). The tool evaluates the extent and intensity of the AD lesions, along with subjective symptoms (Kunz et al, 1997). The total score ranges from 0 to 103, with higher values indicating more severe disease. A negative change from baseline indicates an improvement in severity of disease.
Time frame: Baseline and Week 16
Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16
Pruritus was assessed using an NRS (0-10) with 0 = no itch and 10 = worst imaginable itch. A negative change from baseline indicates an improvement in symptoms.
Time frame: Baseline and Week 16
Serum Trough Concentrations of Tezepelumab After Q2W or Q4W Administration
Switchers were included up to Week 16 and were then excluded from the analysis after switching. All Tezepelumab participants received 420 mg of Tezepelumab on Day 1.
Time frame: Pre-dose on Day 1, Week 2, 4, 12, 16, 24, 32, 40, 48, 50, 52, 58 and 70
Serum Trough Concentrations of Tezepelumab After Switching to 420 mg Q2W Administration After Week 16
Time frame: Pre-dose on Week 24, 32, 40, 48, 50, 52, 58 and 70
Participants were enrolled in 78 centers in 14 countries including Australia, Canada, Czech Republic, Estonia, Germany, Hungary, Japan, Latvia, Poland, Republic of Korea, Spain, Ukraine, the United Kingdom, and the United States.
| Milestone | Part A: Placebo | Part A: Tezepelumab 210 mg Q4W | Part A: Tezepelumab 280 mg Q2W | Part A: Tezepelumab 420 mg Q2W | Part B: Placebo and Topical Corticosteroids Regimen | Part B: Tezepelumab 420 mg Q2W and Topical Corticosteroids Regimen |
|---|---|---|---|---|---|---|
| Started | 63 | 62 | 63 | 63 | 0 | 0 |
| Participants who received investigational product | 63 | 61 | 63 | 63 | 0 | 0 |
| Easi 50 non-responder at week 16 | 40 | 26 | 30 | 38 | 0 | 0 |
| Switched to tezepelumab 420 mg q2w after week 16 | 39 | 24 | 30 | 38 | 0 | 0 |
| Completed | 12 | 18 | 15 | 16 | 0 | 0 |
| Not completed | 51 | 44 | 48 | 47 | 0 | 0 |
| Withdrew: Decision by sponsor | 24 | 18 | 20 | 20 | 0 | 0 |
| Withdrew: Withdrawal by subject | 26 | 22 | 27 | 26 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 4 | 1 | 1 | 0 | 0 |
The IGA allows investigators to assess overall disease severity at 1 given time point and consists of a 6-point severity scale from clear to severe disease * 0 = clear * 1 = almost clear * 2 = mild disease * 3 = moderate disease * 4 = severe disease * 5 = very severe disease The IGA uses clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines for the overall severity assessment (Breuer et al, 2004). Participants who took rescue medication between Day 29 to Week 16 were considered non-responders.
| Participants | Part A: Placebo | Part A: Tezepelumab 210 mg Q4W | Part A: Tezepelumab 280 mg Q2W | Part A: Tezepelumab 420 mg Q2W |
|---|---|---|---|---|
| Number of Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) (IGA 0/1) at Week 16 | 2 | 4 | 2 | 5 |
The EASI evaluates 4 natural anatomical regions for severity and extent of key disease signs and focuses on key acute and chronic signs of inflammation (ie, erythema, induration/papulation, excoriation, and lichenification). A reduction in the EASI score indicates an improvement in severity. Participants who took rescue medication between Day 29 to Week 16 were considered non-responders.
| Participants | Part A: Placebo | Part A: Tezepelumab 210 mg Q4W | Part A: Tezepelumab 280 mg Q2W | Part A: Tezepelumab 420 mg Q2W |
|---|---|---|---|---|
| Number of Participants Who Experienced a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) at Week 16 | 8 | 9 | 10 | 7 |
The EASI evaluates 4 natural anatomical regions for severity and extent of key disease signs and focuses on key acute and chronic signs of inflammation (ie, erythema, induration/papulation, excoriation, and lichenification). A reduction in the EASI score indicates an improvement in severity. Participants who took rescue medication between Day 29 to Week 16 were considered non-responders.
| Participants | Part A: Placebo | Part A: Tezepelumab 210 mg Q4W | Part A: Tezepelumab 280 mg Q2W | Part A: Tezepelumab 420 mg Q2W |
|---|---|---|---|---|
| EASI 50 | 11 | 21 | 18 | 11 |
| EASI 90 | 3 | 3 | 3 | 3 |
| Weeks | Part A: Placebo | Part A: Tezepelumab 210 mg Q4W | Part A: Tezepelumab 280 mg Q2W | Part A: Tezepelumab 420 mg Q2W |
|---|---|---|---|---|
| Time to EASI 50 | 6.143 (4.14 to 19.57) | 8.143 (3.86 to 16.14) | 6.286 (3.86 to 22.14) | 5.857 (3.86 to 16.14) |
| Time to EASI 75 | 6.143 (4.14 to 19.57) | 6.286 (4.00 to 16.43) | 6.714 (4.14 to 22.14) | 6.429 (4.14 to 16.14) |
| Time to EASI 90 | 8.286 (4.43 to 19.57) | 10.929 (4.00 to 16.14) | 10.071 (6.14 to 16.14) | 7.286 (4.14 to 16.29) |
The SCORAD is a clinical tool for assessing the severity (ie, extent, intensity) of atopic dermatitis (AD). The tool evaluates the extent and intensity of the AD lesions, along with subjective symptoms (Kunz et al, 1997). The total score ranges from 0 to 103, with higher values indicating more severe disease. A negative change from baseline indicates an improvement in severity of disease.
| Score on a scale | Part A: Placebo | Part A: Tezepelumab 210 mg Q4W | Part A: Tezepelumab 280 mg Q2W | Part A: Tezepelumab 420 mg Q2W |
|---|---|---|---|---|
| Change From Baseline in Scoring of Atopic Dermatitis (SCORAD) at Week 16 | -8.00 ± 2.55 | -16.75 ± 2.40 | -11.87 ± 2.49 | -9.32 ± 2.48 |
Pruritus was assessed using an NRS (0-10) with 0 = no itch and 10 = worst imaginable itch. A negative change from baseline indicates an improvement in symptoms.
| Score on a scale | Part A: Placebo | Part A: Tezepelumab 210 mg Q4W | Part A: Tezepelumab 280 mg Q2W | Part A: Tezepelumab 420 mg Q2W |
|---|---|---|---|---|
| Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16 | -0.71 ± 0.30 | -1.40 ± 0.27 | -0.94 ± 0.28 | -0.38 ± 0.28 |
Switchers were included up to Week 16 and were then excluded from the analysis after switching. All Tezepelumab participants received 420 mg of Tezepelumab on Day 1.
| µg/mL | Part A: Tezepelumab 210 mg Q4W | Part A: Tezepelumab 280 mg Q2W | Part A: Tezepelumab 420 mg Q2W |
|---|---|---|---|
| Day 1 | 0.00031 ± 0.00236 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Week 2 | 34.9 ± 10.9 | 36.3 ± 12.9 | 34.8 ± 12.9 |
| Week 4 | 23.4 ± 9.03 | 48.8 ± 16.0 | 58.9 ± 21.4 |
| Week 12 | 21.7 ± 8.47 | 66.7 ± 22.9 | 97.0 ± 35.0 |
| Week 16 | 22.2 ± 9.42 | 77.4 ± 33.0 | 98.0 ± 37.8 |
| Week 24 | 23.2 ± 10.6 | 83.6 ± 31.2 | 107 ± 29.5 |
| Week 32 | 25.4 ± 17.0 | 75.1 ± 36.3 | 81.4 ± 26.4 |
| Week 40 | 22.9 ± 12.7 | 76.8 ± 19.7 | 112 ± 63.3 |
| Week 48 | 18.2 ± 6.49 | 76.4 ± 26.4 | 118 ± 48.3 |
| Week 50 | 29.2 ± 9.11 | 86.8 ± 27.7 | 113 ± 44.4 |
| Week 52 | 18.3 ± 7.24 | 67.2 ± 33.2 | 102 ± 31.2 |
| Week 58 | 5.41 ± 2.56 | 18.0 ± 7.09 | 20.9 ± NA |
| Week 70 | 0.699 ± 0.380 | 1.87 ± 1.74 | 5.36 ± 3.20 |
| µg/mL | Part A: Placebo up to Week 16; Tezepelumab 420 mg Week 16 to 52 (Switchers) | Part A: Tezepelumab 210 mg up to Week 16; Tezepelumab 420 mg Week 16 to 52 (Switchers) | Part A: Tezepelumab 280 mg up to Week 16; Tezepelumab 420 mg Week 16 to 52 (Switchers) | Part A: Tezepelumab 420 mg up to Week 16; Tezepelumab 420 mg Week 16 to 52 (Switchers) |
|---|---|---|---|---|
| Week 24 | 70.5 ± 28.3 | 87.2 ± 24.0 | 96.6 ± 29.2 | 100 ± 38.2 |
| Week 32 | 91.0 ± 38.7 | 104 ± 38.8 | 97.8 ± 39.3 | 105 ± 39.1 |
| Week 40 | 117 ± 42.7 | 93.8 ± 35.5 | 113 ± 31.1 | 101 ± 37.7 |
| Week 48 | 134 ± 60.2 | 121 ± 29.1 | 89.6 ± 35.1 | 103 ± 29.9 |
| Week 50 | 115 ± 39.0 | 125 ± 42.2 | 79.1 ± 38.6 | 106 ± 27.0 |
| Week 52 | 125 ± 30.8 | 113 ± 45.0 | 88.3 ± 33.0 | 105 ± 30.2 |
| Week 58 | 26.0 ± 21.6 | 52.6 ± NA | 36.7 ± NA | 17.6 ± 9.28 |
| Week 70 | 5.07 ± 5.10 | 4.47 ± 3.39 | 2.60 ± 1.72 | 3.49 ± 2.42 |
Collected over Up to week 16 for Arms 1-4 and after week 16 up to week 70 for Arms 5-12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/63 (0%) | 0/63 (0%) | 25/63 (39.7%) |
| Tezepelumab 210 mg Q4W | 0/59 (0%) | 2/59 (3.4%) | 20/59 (33.9%) |
| Tezepelumab 280 mg Q2W | 0/58 (0%) | 0/58 (0%) | 29/58 (50%) |
| Tezepelumab 420 mg Q2W | 0/70 (0%) | 1/70 (1.4%) | 30/70 (42.9%) |
| Placebo - Placebo | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Tezepelumab 210 mg Q4W - 210 mg Q4W | 0/25 (0%) | 0/25 (0%) | 10/25 (40%) |
| Tezepelumab 280 mg Q2W - 280 mg Q2W | 0/20 (0%) | 1/20 (5%) | 11/20 (55%) |
| Tezepelumab 420 mg Q2W - 420 mg Q2W | 0/22 (0%) | 0/22 (0%) | 5/22 (22.7%) |
| Placebo- Tezepelumab 420 mg Q2W | 0/39 (0%) | 2/39 (5.1%) | 18/39 (46.2%) |
| Tezepelumab 210 mg Q4W-420 mg Q2W | 0/24 (0%) | 0/24 (0%) | 9/24 (37.5%) |
| Tezepelumab 280 mg Q2W-420 mg Q2W | 0/30 (0%) | 1/30 (3.3%) | 10/30 (33.3%) |
| Tezepelumab 420 mg Q2W-420 mg Q2W | 0/38 (0%) | 4/38 (10.5%) | 19/38 (50%) |
| Event | Placebo | Tezepelumab 210 mg Q4W | Tezepelumab 280 mg Q2W | Tezepelumab 420 mg Q2W | Placebo - Placebo | Tezepelumab 210 mg Q4W - 210 mg Q4W | Tezepelumab 280 mg Q2W - 280 mg Q2W | Tezepelumab 420 mg Q2W - 420 mg Q2W | Placebo- Tezepelumab 420 mg Q2W | Tezepelumab 210 mg Q4W-420 mg Q2W | Tezepelumab 280 mg Q2W-420 mg Q2W | Tezepelumab 420 mg Q2W-420 mg Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alcohol abusePsychiatric disorders | 0/63 | 0/59 | 0/58 | 0/70 | 0/12 | 0/25 | 0/20 | 0/22 | 0/39 | 0/24 | 0/30 | 2/38 |
| AscitesGastrointestinal disorders | 0/63 | 0/59 | 0/58 | 0/70 | 0/12 | 0/25 | 1/20 | 0/22 | 0/39 | 0/24 | 0/30 | 0/38 |
| Hepatic cirrhosisHepatobiliary disorders | 0/63 | 0/59 | 0/58 | 0/70 | 0/12 | 0/25 | 1/20 | 0/22 | 0/39 | 0/24 | 0/30 | 0/38 |
| CellulitisInfections and infestations | 0/63 | 0/59 | 0/58 | 0/70 | 0/12 | 0/25 | 1/20 | 0/22 | 0/39 | 0/24 | 0/30 | 0/38 |
| Device failureProduct Issues | 0/63 | 0/59 | 0/58 | 0/70 | 0/12 | 0/25 | 1/20 | 0/22 | 0/39 | 0/24 | 0/30 | 0/38 |
| Skin erosionSkin and subcutaneous tissue disorders | 0/63 | 0/59 | 0/58 | 0/70 | 0/12 | 0/25 | 1/20 | 0/22 | 0/39 | 0/24 | 0/30 | 0/38 |
| Corneal degenerationEye disorders | 0/63 | 0/59 | 0/58 | 0/70 | 0/12 | 0/25 | 0/20 | 0/22 | 0/39 | 0/24 | 1/30 | 0/38 |
| COVID-19 pneumoniaInfections and infestations | 0/63 | 0/59 | 0/58 | 0/70 | 0/12 | 0/25 | 0/20 | 0/22 | 0/39 | 0/24 | 0/30 | 1/38 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/63 | 1/59 | 0/58 | 0/70 | 0/12 | 0/25 | 0/20 | 0/22 | 1/39 | 0/24 | 0/30 | 1/38 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/63 | 0/59 | 0/58 | 0/70 | 0/12 | 0/25 | 0/20 | 0/22 | 1/39 | 0/24 | 0/30 | 0/38 |
| Event | Placebo | Tezepelumab 210 mg Q4W | Tezepelumab 280 mg Q2W | Tezepelumab 420 mg Q2W | Placebo - Placebo | Tezepelumab 210 mg Q4W - 210 mg Q4W | Tezepelumab 280 mg Q2W - 280 mg Q2W | Tezepelumab 420 mg Q2W - 420 mg Q2W | Placebo- Tezepelumab 420 mg Q2W | Tezepelumab 210 mg Q4W-420 mg Q2W | Tezepelumab 280 mg Q2W-420 mg Q2W | Tezepelumab 420 mg Q2W-420 mg Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 12/63 | 9/59 | 13/58 | 13/70 | 2/12 | 5/25 | 2/20 | 3/22 | 9/39 | 2/24 | 4/30 | 6/38 |
| NasopharyngitisInfections and infestations | 6/63 | 5/59 | 10/58 | 6/70 | 0/12 | 3/25 | 3/20 | 3/22 | 3/39 | 0/24 | 3/30 | 3/38 |
| HeadacheNervous system disorders | 3/63 | 1/59 | 1/58 | 4/70 | 0/12 | 0/25 | 0/20 | 0/22 | 4/39 | 1/24 | 0/30 | 2/38 |
| Upper respiratory tract infectionInfections and infestations | 4/63 | 3/59 | 2/58 | 1/70 | 0/12 | 1/25 | 2/20 | 0/22 | 2/39 | 1/24 | 0/30 | 1/38 |
| Urinary tract infectionInfections and infestations | 0/63 | 2/59 | 0/58 | 1/70 | 0/12 | 0/25 | 0/20 | 2/22 | 0/39 | 1/24 | 0/30 | 0/38 |
| Condition aggravatedGeneral disorders | 1/63 | 0/59 | 1/58 | 0/70 | 1/12 | 0/25 | 0/20 | 0/22 | 0/39 | 0/24 | 0/30 | 0/38 |
| CellulitisInfections and infestations | 0/63 | 1/59 | 0/58 | 0/70 | 1/12 | 0/25 | 0/20 | 0/22 | 2/39 | 1/24 | 0/30 | 1/38 |
| ConjunctivitisInfections and infestations | 0/63 | 2/59 | 0/58 | 2/70 | 0/12 | 0/25 | 0/20 | 0/22 | 0/39 | 2/24 | 0/30 | 2/38 |
| Eczema herpeticumInfections and infestations | 2/63 | 0/59 | 1/58 | 0/70 | 1/12 | 0/25 | 0/20 | 0/22 | 0/39 | 0/24 | 1/30 | 0/38 |
| Otitis mediaInfections and infestations | 0/63 | 1/59 | 0/58 | 0/70 | 0/12 | 0/25 | 0/20 | 0/22 | 0/39 | 2/24 | 0/30 | 0/38 |
Full analysis set (FAS): All randomized participants in Part A.
| Age, Continuous(Years) | Part A: Placebo | Part A: Tezepelumab 210 mg Q4W | Part A: Tezepelumab 280 mg Q2W | Part A: Tezepelumab 420 mg Q2W | Total |
|---|---|---|---|---|---|
| Mean | 35.7 ± 13.4 | 38.5 ± 15.0 | 36.9 ± 13.4 | 40.7 ± 14.3 | 37.9 ± 14.1 |
| Sex: Female, Male(Participants) | Part A: Placebo | Part A: Tezepelumab 210 mg Q4W | Part A: Tezepelumab 280 mg Q2W | Part A: Tezepelumab 420 mg Q2W | Total |
|---|---|---|---|---|---|
| Female | 27 | 32 | 23 | 27 | 109 |
| Male | 36 | 30 | 40 | 36 | 142 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Placebo | Part A: Tezepelumab 210 mg Q4W | Part A: Tezepelumab 280 mg Q2W | Part A: Tezepelumab 420 mg Q2W | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 4 | 1 | 4 | 15 |
| Not Hispanic or Latino | 57 | 58 | 62 | 59 | 236 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Part A: Placebo | Part A: Tezepelumab 210 mg Q4W | Part A: Tezepelumab 280 mg Q2W | Part A: Tezepelumab 420 mg Q2W | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 21 | 16 | 16 | 13 | 66 |
| Black or African-American | 1 | 3 | 1 | 3 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| White | 41 | 42 | 45 | 47 | 175 |
| Unknown | 0 | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 1 | 0 | 1 |
| Investigator's Global Assessment Score(Participants) | Part A: Placebo | Part A: Tezepelumab 210 mg Q4W | Part A: Tezepelumab 280 mg Q2W | Part A: Tezepelumab 420 mg Q2W | Total |
|---|---|---|---|---|---|
| IGA Score of 3 | 26 | 37 | 26 | 37 | 126 |
| IGA Score of 4 | 32 | 17 | 30 | 18 | 97 |
| IGA Score of 5 | 5 | 8 | 7 | 8 | 28 |
| Eczema Area and Severity Index (EASI)(Score on a scale) | Part A: Placebo | Part A: Tezepelumab 210 mg Q4W | Part A: Tezepelumab 280 mg Q2W | Part A: Tezepelumab 420 mg Q2W | Total |
|---|---|---|---|---|---|
| Mean | 32.0 ± 11.1 | 28.4 ± 13.2 | 30.3 ± 10.7 | 28.6 ± 12.4 | 29.8 ± 11.9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Mar 2019 to primary completion in May 2020, 13 months.
Results were first posted in Mar 2022, 1 year 9 months after primary completion. A results delay was requested in Feb 2021.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab